Carnitine palmitoyltransferase II deficiency
Nov. 24, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Hepatorenal tyrosinemia …
- Updated 05.14.2024
- Released 06.01.2013
- Expires For CME 05.14.2027
Hepatorenal tyrosinemia
Introduction
Overview
In this article, the author explains the clinical and genetic background of hepatorenal tyrosinemia. Hepatorenal tyrosinemia is an inborn metabolic disease caused by a defective fumarylacetoacetate hydrolase enzyme, the last enzyme of the tyrosine degradation pathway. Untreated, hepatorenal tyrosinemia can lead to hepatocellular carcinoma.
Key points
|
• Hepatorenal tyrosinemia, or tyrosinemia type 1, is the most severe form of genetic tyrosinemia. | |
|
• Hepatorenal tyrosinemia is a devastating disorder of childhood that causes liver failure, painful porphyria-like neurologic crises, hypophosphatemic rickets, Fanconi syndrome, and hepatocellular carcinoma. | |
|
• If untreated, death typically occurs before 2 years of age, although some milder forms allow longer survival. | |
|
• Hepatorenal tyrosinemia is caused by defective fumarylacetoacetate hydrolase. | |
|
• The pathognomonic metabolite for hepatorenal tyrosinemia is succinylacetone. | |
|
• Secondary enzyme deficiencies in hepatorenal tyrosinemia (ie, delta-aminolevulinic acid dehydratase, methionine adenosyl transferase) result from inhibition by metabolites (ie, succinylacetone and fumarylacetoacetate), accumulating as a result of a primary deficiency of fumarylacetoacetate hydrolase. The secondary enzyme deficiency in delta-aminolevulinic acid dehydratase links tyrosinemia with porphyrin synthesis and is responsible for the porphyria-like crises in tyrosinemia. | |
|
• Hepatorenal tyrosinemia is treated by nitisinone administration and restriction of dietary tyrosine and phenylalanine. Occasionally, orthotopic hepatic transplantation may be indicated. |
Historical note and terminology
Tyrosine (from the Greek tyros, meaning cheese), or 4-hydroxy-phenylalanine, was discovered in 1846 by German chemist Justus Freiherr von Liebig (1803-1873) in the protein casein from cheese.
Tyrosine is a nonessential amino acid with a polar side group, one of the 22 amino acids that are used by cells to synthesize proteins. Tyrosine phosphorylation, mediated by protein kinases (so-called receptor tyrosine kinases), is one of the key steps in signal transduction and regulation of enzymatic activity. Tyrosine is also a precursor to neurotransmitters (ie, catecholamines) and hormones (ie, thyroxine and melatonin), and, in particular, in dopaminergic cells in the brain, tyrosine is converted to L-DOPA by the enzyme tyrosine hydroxylase, and L-DOPA can in turn be converted to dopamine, noradrenaline (norepinephrine), and adrenaline (epinephrine).
In 1932, American biochemist Grace Medes (1886-1967), at the University of Minnesota Medical School in Minneapolis, first described “a new disorder of tyrosine metabolism” and called it “tyrosinosis” after observing 4-hydroxyphenylpyruvate in the urine of a 49-year-old man with myasthenia gravis (58). She proposed that the metabolic defect in this patient was a deficiency of 4-hydroxyphenylpyruvate dioxygenase, but the case remains puzzling and has since been assigned a separate OMIM number (76800) (48).
The first typical patient with hepatorenal tyrosinemia was described in 1956 by Margaret D Baber at Edgware General Hospital in Middlesex, England (06). Starting the following year, Kiyoshi Sakai and colleagues, at the Jikei University School of Medicine in Tokyo, published three reports describing the clinical, biochemical, and pathological findings of a 2-year-old boy with hepatorenal tyrosinemia who was then thought to have an “atypical” case of tyrosinosis (“atypical” because it differed from the supposedly prototypical case reported by Medes) (75; 76; 77; 48).
Then, between 1963 and 1965, Swedish pediatrician Rolf Zetterström (1920-2011) and associates at the Karolinska Institutet in Sweden published the first detailed descriptions of hepatorenal tyrosinemia and its variants, a disorder then hypothesized to be caused by a defective 4-hydroxyphenylpyruvate dioxygenase enzyme (102; 35; 45; 36; 39; 91). Shortly thereafter, a Canadian group also described the clinical and laboratory findings of hepatorenal tyrosinemia (83). Both the Scandinavian and Canadian groups suggested that the Japanese patients described earlier by Sakai and colleagues had the same disorder, ie, hepatorenal tyrosinemia (48).
From 1965, doubts arose over the hypothesis that hepatorenal tyrosinemia is caused by a defective 4-hydroxyphenylpyruvate dioxygenase enzyme, but it was not until 1977 that Bengt Lindblad and colleagues at the University of Gothenburg in Sweden showed that the primary enzyme defect in hepatorenal tyrosinemia involved the fumarylacetoacetate hydrolase enzyme (55). This was subsequently confirmed with a direct enzyme assay.
Clinical manifestations
Presentation and course
Untreated, most patients with hepatorenal tyrosinemia become symptomatic within the first few months of life, but patients can present as late as 6 months of age (46; 82). Failure to thrive usually precedes the appearance of more severe findings. Clinical presentations vary from early-onset acute liver failure with severe coagulopathy, to slowly progressing cirrhosis with multiple nodules and variable renal dysfunction, to normal liver function with renal failure (54; 66). One third of cases develop hepatocellular carcinoma (66; 46). Untreated patients have a peculiar “cabbage-like” odor to the skin or urine. Other manifestations can include porphyria-like neurologic crises, rickets, and cardiomyopathy (38; 37; 55; 46; 62).
In a study of 22 affected children from Finland, the median age at diagnosis was 5 months, with an approximately equal gender distribution (55% were girls) (01). Four patients were detected through screening and 18 clinically. Thirteen (59%) had a homozygous Finnish type c.786G>A, (p.Trp262X) mutation. The main findings were liver failure, ascites, renal tubulopathy, rickets, growth failure, thrombocytopenia, and anemia. Three patients needed transplantation later. Kidney dysfunction, hypertension, and osteopenia/osteoporosis were more frequent in transplanted than in nitisinone-treated patients.
Due to the effect of succinylacetone on heme-metabolism, porphyria-like neurologic crises can also occur (38; 37; 55; 82). However, treatment of patients with nitisinone prevents the development of acute hepatic and neurologic crises.
Historically, patients with hepatorenal tyrosinemia were classified as “acute” or “chronic,” with patients classified as “chronic” when they survived more than 2 years on medical treatment. Classification of patients with hepatorenal tyrosinemia in this manner may be deceptive because patients classified as acute in the first year of life may survive with a chronic course. Conversely, patients classified as chronic may still experience life-threatening neurologic and hepatic crises.
Van Spronsen and colleagues proposed the classification of hepatorenal tyrosinemia as very early-, early-, and late-presenting based on the time of the onset of symptoms (less than 2 months, 2-6 months, and more than 6 months, respectively) (95). Similarly, Demers and colleagues classified hepatorenal tyrosinemia as acute, subacute, and chronic based on the time of liver transplantation. With the Demers classification, patients undergoing liver transplantation before 2 years of age are classified as acute, between the ages of 2 and 6 as subacute, and after 6 years of age as chronic (29).
Fanconi-Debré-de Toni syndrome (also known as Fanconi renotubular syndrome, or FRST) often presents as a secondary feature of tyrosinemia and other systemic disorders that impair energy supply (eg, Lowe syndrome, Dent disease, cystinosis, hereditary fructose intolerance, galactosemia, Alport syndrome, and Wilson disease) (11; 60; 57; 32; 34; 65; 02). Fanconi syndrome is a defect of the proximal renal tubule leading to malabsorption of various electrolytes and substances that are usually absorbed by the proximal tubule (eg, water, calcium, bicarbonate, phosphate, potassium, glucose, uric acid, amino acids, etc.). Various animal models of tyrosinemia have been employed to elaborate the mechanism of Fanconi syndrome development in tyrosinemia (87; 86; 74; 73; 72; 71; 99; 98; 89; 63). Succinylacetone, a metabolite of tyrosine excreted in excess by infants and children with hereditary tyrosinemia and the renal Fanconi syndrome, was found to impair sugar and amino acid uptake by both newborn renal tubules and 7-day renal brush-border membrane vesicles (BBMV) (87; 73). Succinylacetone administration in experimental models was also associated with glucosuria, polyuria, and reduced renal phosphate reabsorption (98).
Although the introduction of newborn screening programs and nitisinone treatment has altered the clinical course of hepatorenal tyrosinemia by making early detection and treatment possible, natural disease progression is still seen in many parts of the world where early screening and treatment are not available (34). In addition, even with appropriate treatment, patients develop several behavior problems and have a lower-than-normal health-related quality of life (96).
Prognosis and complications
The prognosis of type 1 tyrosinemia has improved with the advent of nitisinone, particularly when combined with newborn screening to identify cases early (01). Nevertheless, there is a long-term risk for complications, particularly with late diagnosis or insufficient nitisinone levels.
Clinical vignette
In 1955, a 2-year-old boy was admitted with marked hepatosplenomegaly and failure to thrive (75; 76; 77; 48). He was the second child of a consanguineous marriage and was a normal term delivery and at birth weighed 3900 grams. Although he grew and developed normally as an infant, during his second year his parents noticed a loss of appetite and gradually increasing abdominal distension. Routine laboratory tests were normal, except for low serum inorganic phosphorus and slightly elevated liver function test results. His urine contained a large amount of 4-hydroxyphenyllactate (4-HPL) and small amounts of 4-hydroxyphenylpyruvate (4-HPP), 4-hydroxyphenylacetate (4-HPA), and tyrosine.
His weight gradually decreased, and he developed rachitic changes, including genu valgum, evident clinically and confirmed by x-rays. From clinical observations and persistent hypophosphatemia, Fanconi syndrome (nephrotic-glucosuric dwarfism with hypophosphatemic rickets) was suspected. He had a series of infections, and ultimately developed hepatic coma and died in November 1957. At autopsy, the liver showed portal cirrhosis with malignant hepatoma. The tyrosine oxidation activity of a liver homogenate (obtained from a liver biopsy 1 hour after death) was only about 20% of normal.
Biological basis
|
• Hepatorenal tyrosinemia is a monogenic disorder with an autosomal recessive pattern of inheritance. | |
|
• Compound heterozygotes for c.1021C > T (p.Arg341Trp) and a severely deficient FAH allele had only mild hypersuccinylacetonemia and remained asymptomatic and clinically normal without nitisinone or dietary treatment for ages 9 to 15 years. |
Etiology and pathogenesis
Hepatorenal tyrosinemia is a monogenic disorder with an autosomal recessive pattern of inheritance. The disease is caused by reduced activity of fumarylacetoacetate hydrolase (FAH, E.C.3.7.1.2), the last enzyme of the tyrosine degradation pathway (55).
In some series, a high proportion of cases occur as a result of consanguineous unions; for example, in an Egyptian report of 76 cases from 70 families, consanguinity was identified in 61 affected families (31).
The FAH gene is located on chromosome 15q25.1. The gene spans over 35 kb of DNA and has five protein-coding transcripts.
Numerous mutations responsible for hepatorenal tyrosinemia have been identified in FAH, including nucleotide substitutions (missense and nonsense), splicing mutations, gross deletions, and small indels (ie, insertions or deletions of bases) (68; 51; 50; 70; 69; 14; 30; 29; 18; 21; 44; 22; 24). Mutations are referenced at the Human Genome Mutation Database (HGMD®).
Reversions to wild-type allele have been reported for some hepatorenal tyrosinemia mutations, including the following: NM_000137.2:c.1062+5G>A, NM_000137.2:c.192G>T, NM_000137.2:c.1009G>A, and NM_000137.2:c.836A>G (51; 50; 69; 30; 29; 18; 21). This reversion of one allele to the wild-type is sufficient to re-establish a normal metabolic milieu, giving such cells a growth advantage over cells with non-corrected mutations. FAH-immunopositive nodules are found in the livers of a large majority (88%) of affected patients (50; 29), thereby creating a liver mosaic.
FAH is a soluble cytosolic homodimer of 46.3 kDa subunits (52). It is predominantly expressed in the liver but is also found in a wide range of tissue and cell types, including brain and skeletal muscle (12; 15).
In the absence of FAH, various metabolites accumulate, including fumarylacetoacetate, maleylacetoacetate, homogentisate, p-hydroxyphenylpyruvate, p-hydroxyphenyllactate, p-hydroxyphenylacetate, and succinylacetone (46). In addition, the absence of FAH activity leads to oxidative damage in the liver that progresses to liver failure and hepatocarcinoma, renal injury, and neurologic crises (42).
In hepatorenal tyrosinemia, secondary enzymes are inhibited (ie, porphobilinogen synthase and methionine adenosyl transferase) by accumulating metabolites (ie, succinylacetone and fumarylacetoacetate) resulting from the primary deficiency of fumarylacetoacetate hydrolase (55; 26; 79; 13; 80; 78; 66). For example, a secondary deficiency of porphobilinogen synthase (ALA dehydratase, aminolevulinate dehydratase; EC 4.2.1.24), the second enzymatic step in the synthesis of porphyrin, results mainly from inhibition by succinylacetone (4,6-dioxoheptanoic acid), and to a lesser degree by fumarylacetoacetate (55; 26; 79; 13; 78; 66).
Succinylacetone is formed from a buildup in the metabolites maleylacetoacetate and fumarylacetoacetate (55; 26; 79; 78; 66).
Because of the inhibition of the cytosolic enzyme porphobilinogen synthase by succinylacetone, patients with hepatorenal tyrosinemia build up and excrete 5-aminolevulinic acid, as do patients in whom the activity of this enzyme is disturbed for other reasons (eg, acute intermittent porphyria, porphyria variegata, hereditary coproporphyria, and lead intoxication) (49). This process of secondary enzyme inhibition effectively links tyrosinemia with porphyrin synthesis and is responsible for the porphyria-like neurologic crises in patients with hepatorenal tyrosinemia (13). Similarly, the secondary enzyme deficiency in methionine adenosyl transferase (by succinylacetone) results in elevated methionine levels (13).
Mitochondrial and cytosolic components of porphyrin/heme synthesis
In hepatorenal tyrosinemia, the cytosolic enzyme porphobilinogen synthase (ALA dehydratase, aminolevulinate dehydratase), top right of figure, is strongly inhibited by succinylacetone, producing an accumulation of δ-aminolevulinic...
Compound heterozygotes for c.1021C > T (p.Arg341Trp) and a severely deficient FAH allele had only mild hypersuccinylacetonemia and remained asymptomatic and clinically normal without nitisinone or dietary treatment for ages 9 to 15 years (101).
Epidemiology
|
• Hepatorenal tyrosinemia generally affects about 1 in 100,000 newborns. | |
|
• Due to a complex founder effect, hepatorenal tyrosinemia is much more common in French Canadians. |
Hepatorenal tyrosinemia generally affects about 1 in 100,000 newborns (42; 05; 20; 01), but it differs somewhat in different populations. For example, the incidence is estimated at 1 in 74,800 births among Norwegians (18) and between 2.2 and 4.9 per 100,000 births among Emiratis (04). Due to a complex founder effect, hepatorenal tyrosinemia is much more common in French Canadians (53; 16; 43), clustering particularly in the Saguenay-Lac-St.-Jean area of Quebec, where the incidence is more than 1 in 2000 newborns, and where 1 of every 22 persons is a carrier (43). It is also relatively common in Tunisia, where the incidence is approximately 1 in 15,000 births (64).
Differential diagnosis
Hypertyrosinemia may be caused by several different conditions, including severe hepatocellular dysfunction, transient tyrosinemia of the newborn, inborn errors of tyrosine catabolism (hepatorenal tyrosinemia, oculocutaneous tyrosinemia, 4-HPPD deficiency), nitisinone treatment, scurvy, hyperthyroidism, and the postprandial state. In cirrhosis and acute liver failure, plasma tyrosine and methionine may both be nonspecifically elevated. Concurrent hepatorenal failure and renal tubular dysfunction may also be seen in other inherited diseases, (eg, galactosemia, hereditary fructose intolerance, lactic acidosis, and glycogen storage disease type IV).
All of the genetic tyrosinemias are characterized by accumulation of tyrosine in body fluids and tissues, and excretion of characteristic tyrosine metabolites in urine (82). Oculocutaneous tyrosinemia (type II), caused by deficiency of tyrosine aminotransferase (TAT) encoded by the TAT gene on chromosome 16q22.1, presents with photophobia (resulting from deposition of tyrosine crystals in the cornea) and hyperkeratotic plaques on the hands and soles of the feet.
Tyrosinemia type III, a very rare condition caused by a deficiency of 4-hydroxyphenylpyruvic dioxygenase (4-HPD) encoded by the HPD gene on chromosome 12q24.31, manifests with ataxia and mild intellectual disability.
Urine organic acids show elevated p-hydroxy-phenyl organic acids in each type of tyrosinemia, and pathognomic succinylacetone in hepatorenal tyrosinemia (tyrosinemia type I) (82). Methionine is also elevated in hepatorenal tyrosinemia, reflecting impaired hepatocellular function (82).
Diagnostic workup
• Clinical features of hepatorenal tyrosinemia include severe liver dysfunction in infancy. | |
• Porphyria-like neurologic crises, hypophosphatemic rickets, and other renal tubular diseases may also suggest the diagnosis of hepatorenal tyrosinemia, especially if found in combination with liver dysfunction. | |
• A high level of succinylacetone in blood, plasma, or urine is characteristic of hepatorenal tyrosinemia. | |
• Diagnosis of hepatorenal tyrosinemia has to be confirmed with enzyme or mutation assays of FAH. These assays can be performed on liver biopsies, lymphocytes, fibroblasts, or dried blood spots. | |
• Targeted mutation analysis or sequence analysis may be performed to confirm hepatorenal tyrosinemia. | |
• Prenatal diagnosis of hepatorenal tyrosinemia may be obtained by either determination of succinylacetone in amniotic fluid, an FAH assay, or molecular analysis in amniocytes of chorionic villi. | |
• Neonatal screening for hepatorenal tyrosinemia is performed by one of two approaches: screening for elevated blood tyrosine and methionine levels or screening for more specific indicators, such as succinylacetone or delta-ALA-dehydratase (PBG synthase) enzyme activity. | |
• Hepatocellular carcinoma should be suspected in patients with hepatorenal tyrosinemia when there are increased alpha1-fetoprotein levels and characteristic imaging features, but a high index of suspicion is needed when imaging features change without a clear increase in alpha1-fetoprotein. |
Clinical features of hepatorenal tyrosinemia include severe liver dysfunction in infancy. Porphyria-like neurologic crises, hypophosphatemic rickets, and other renal tubular diseases may also suggest the diagnosis of hepatorenal tyrosinemia, especially if found in combination with liver dysfunction. A high level of succinylacetone in blood, plasma, or urine is characteristic of hepatorenal tyrosinemia (41) but can also occur with impaired function of maleylacetoacetate isomerase (ie, due to loss of function mutations in the GSTZ1 gene), the enzyme preceding fumarylacetoacetate hydrolase in tyrosine degradation (100). Elevated plasma levels of tyrosine, phenylalanine, and methionine, and elevated urinary levels of p-hydroxyphenylpyruvate, p-hydroxyphenyllactate, p-hydroxyphenylacetate, and δ-aminolevulinic acid, may also be detected (46). Elevated urinary and plasma succinylacetone levels may persist even after orthotopic liver transplantation (09).
Diagnosis of hepatorenal tyrosinemia has to be confirmed with enzyme or mutation assays of FAH. These assays can be performed on liver biopsies, lymphocytes, fibroblasts, or dried blood spots (33).
Targeted mutation analysis or sequence analysis may be performed to confirm hepatorenal tyrosinemia. Four common mutations (NM_000137.2:c.1062+5G> A, NM_000137.2:c.554-1G> T, NM_000137.2:c.607-6T> G, NM_000137.2:c.782C> T) account for 60% of hepatorenal tyrosinemia mutations in the United States, Europe, Morocco, and Turley. The NM_000137.2:c.782C>T mutation is found in almost 100% of patients with hepatorenal tyrosinemia in the Ashkenazi Jewish population, and the NM_000137.2:c.1062+5G>A accounts for 90% of mutations in the French-Canadian population. In Norway, 65% of patients with hepatorenal tyrosinemia are compound heterozygous for different mutations (18).
Prenatal diagnosis of hepatorenal tyrosinemia may be obtained by either determination of succinylacetone in amniotic fluid, an FAH assay, or molecular analysis in amniocytes of chorionic villi (90).
Neonatal screening for hepatorenal tyrosinemia is performed by one of two approaches: screening for elevated blood tyrosine and methionine levels or screening for more specific indicators, such as succinylacetone or delta-ALA-dehydratase (PBG synthase) enzyme activity (46). There is now strong consensus in favor of newborn screening for hepatorenal tyrosinemia (hereditary tyrosinemia type I; HT-1) using blood succinylacetone as a marker, followed by diagnostic confirmation and early treatment with nitisinone and diet.
Hepatocellular carcinoma should be suspected in patients with hepatorenal tyrosinemia when there are increased alpha1-fetoprotein levels and characteristic imaging features, but a high index of suspicion is needed when imaging features change without a clear increase in alpha1-fetoprotein (92).
Management
|
• Standard treatment for hepatorenal tyrosinemia consists of protein-restricted diet with administration of nitisinone or NTBC. | |
|
• Initiating treatment of NTBC before 6 months of age significantly reduces the risk of development of hepatocellular carcinoma, improves renal tubular dysfunction, and preserves renal function even after orthotopic liver transplantation. |
Standard treatment for hepatorenal tyrosinemia consists of protein-restricted diet with administration of nitisinone or NTBC [2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione] (03; 25; 28; 61).
Diet. An international group of nutrition specialists now advocates for a simplified low-protein diet and to allow more natural protein intake (07). Preliminary data indicate that simplification of the diet with increased natural protein intake based on three categories of food may be implemented in the diet of patients with tyrosinemia type 1 without significantly altering metabolic control. Compliance with dietary recommendations was higher using the simplified diet in comparison to the stricter approach.
Casein glycomacropeptide (CGMP), a bioactive peptide, is an alternative protein source to traditional amino acids. CGMP contains residual tyrosine and phenylalanine and requires supplementation with tryptophan, histidine, methionine, leucine, cysteine, and arginine. In a 12-month study in children with hepatorenal tyrosinemia, CGMP was well tolerated, with no deterioration in metabolic control or growth (27).
Nitisinone (NTBC). Typically, the starting dose of NTBC is 1.0 mg/kg per day divided into two doses. However, Schlune and colleagues suggested that a single dose may be as effective as multiple daily doses (81). To be of therapeutic value, the level of NTBC in the blood should be between 40 and 60 µmol/L. As long as this level is maintained, succinylacetone levels in urine do not need to be monitored.
NTBC blocks the accumulation of toxic metabolites by inhibiting the 4-hydroxyphenylpyruvate dioxygenase enzyme (4HPPD), an Fe(II)-containing non-heme oxygenase that catalyzes the second reaction in the catabolism of tyrosine: conversion of 4-hydroxyphenylpyruvate into homogentisate. Inhibition of 4-HPPD prevents tyrosine degradation and results in decreases of fumarylacetoacetate, maleylacetoacetate, succinylacetone, and δ-aminolevulinate concentrations (47) (step 3 in diagram).
Concentrations of p-hydroxyphenyllactate and tyrosine may increase after inhibition of 4HPPD. Therefore, dietary intake of phenylalanine and tyrosine should be restricted based on plasma levels. Factors such as growth rate, protein and energy intake, and health may influence the tyrosine and phenylalanine requirements of an individual. The concentration of plasma tyrosine and phenylalanine should be controlled with diet to levels of 200-500 µmol/L and 20-80 µmol/L, respectively.
Initiating treatment of NTBC before 6 months of age significantly reduces the risk of development of hepatocellular carcinoma (33), prevents life-limiting hepatic disease (88), improves renal tubular dysfunction (56), and preserves renal function even after orthotopic liver transplantation (08). However, the long-term effects of NTBC treatment are unknown. In patients who do not respond to NTBC treatment, orthotopic liver transplantation may be necessary (33).
Poor compliance with dietary and pharmacological therapy in hepatorenal tyrosinemia is a major issue that adversely impacts clinical outcomes in this disease. In a Finnish study of 22 patients, low mean nitisinone concentration (ie, typically indicating poor medication compliance) was associated with a higher risk of severe complications (01). Treatment compliance worsens with age (88). Nevertheless, despite initial poor adherence to dietary and pharmacological treatment, positive reinforcement at medical consultations can produce marked improvement in NTBC levels, clearly demonstrating the importance and utility of systematic positive reinforcement at medical visits (40).
Orthotopic liver transplantation. Because orthotopic liver transplantation is associated with significant risks and complications, it should only be considered for patients who do not respond to NTBC treatment (eg, persistent neurologic crises), and for patients who develop severe liver or hepatocellular carcinoma (66; 46; 84; 17). Treatment with NTBC prior to orthotopic liver transplantation may, however, preserve renal function (08). Combined liver and kidney transplantations have also been performed in some cases with both hepatic and renal failure (66).
Some have, nevertheless, argued for use of liver transplantation as a "safe and definitive alternative to lifelong nitisinone [therapy]," especially when nitisinone is unavailable or prohibitively expensive (90; 59). Because orthotopic liver transplantation can be curative for hepatorenal tyrosinemia, and because excellent results can be obtained in experienced centers, liver transplantation is "especially favorable in countries with limited resources where the cost of medical therapy is highly prohibitive, with lifelong diet restrictions and unclear long-term risk of [hepatocellular carcinoma]" (59).
Gene therapy. Preclinical studies for viral-mediated gene transfer for correction of hepatorenal tyrosinemia have shown limited success (67; 97; 85). Animal studies have also provided support for the use of dendrimer-based lipid nanoparticles to deliver therapeutic fumarylacetoacetate hydrolase mRNA to normalize liver function and extend survival (23).
Outcomes
If untreated, hepatorenal tyrosinemia has a high mortality rate. Patients with early-onset hepatorenal tyrosinemia who do not receive treatment often die of chronic hepatic failure by 2 years of age. Similarly, in untreated patients with later-onset hepatorenal tyrosinemia, death may occur in childhood as the result of hepatic failure or hepatocellular carcinoma.
Treatment of patients with a phenylalanine-and-tyrosine-restricted diet reversed renal tubular dysfunction, and restored erythrocyte ALA dehydratase activity toward normal, but there was a less clear effect on liver function, even when the diet was started at an early age (19; 79; 80). Phenylalanine supplementation of 20 mg/kg/day in combination with phenylalanine-tyrosine free L-amino acid supplements can prevent most low phenylalanine concentrations without increasing tyrosine to concentrations above the target range or influencing NTBC and succinylacetone concentrations whereas 40 mg/kg/day increases tyrosine concentrations to values above the targeted range (94).
Treatment with NTBC should start as soon as possible after diagnosis. Metabolic and neurologic decompensations and the need for orthotopic liver transplantation are markedly diminished or abolished by treatment with NTBC (08). If started early, NTBC can prevent liver failure, renal problems, and neurologic attacks and decrease the risk for hepatocellular carcinoma (93). However, NTBC treatment and a protein-restricted diet may not prevent impaired cognitive function (10).
As demonstrated in a noninterventional, noncomparative, multicenter study in 77 sites across 17 countries in Europe, long-term NTBC treatment is well tolerated (88).
Treatment with NTBC and dietary phenylalanine and tyrosine restriction improves physical health and life expectancy in tyrosinemia type 1 but the neurocognitive outcome continues to be suboptimal (96).
Special considerations
Pregnancy
Limited information is available on the treatment of women with hepatorenal tyrosinemia during pregnancy and the puerperium. Nitisinone therapy during pregnancy and the short breastfeeding period did not result in adverse events in a 20-year-old woman with hepatorenal tyrosinemia or her children (103).
Regular assessments of tyrosine, succinylacetone, and nitisinone should be made during pregnancy and the breastfeeding period in both the mother and the infant (103). Additionally, even though experience with breastfeeding is limited for women taking nitisinone, there is no reason to consider breastfeeding unsafe or to not recommend it.
Media
References
- 01
- Aarela L, Hiltunen P, Soini T, et al. Type 1 tyrosinemia in Finland: a nationwide study. Orphanet J Rare Dis 2020;15(1):281. PMID 33046095
- 02
- Albuquerque ALB, Dos Santos Borges R, Conegundes AF, et al. Inherited Fanconi syndrome. World J Pediatr 2023;19(7):619-34. PMID 36729281
- 03
- Al-Dhalimy M, Overturf K, Finegold M, Grompe M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002;75(1):38-45. PMID 11825062
- 04
- Al-Shamsi A, Hertecant JL, Al-Hamad S, Souid AK, Al-Jasmi F. Mutation spectrum and birth prevalence of inborn errors of metabolism among Emiratis: a study from Tawam Hospital Metabolic Center, United Arab Emirates. Sultan Qaboos Univ Med J 2014;14(1):e42-9. PMID 24516753
- 05
- Angileri F, Bergeron A, Morrow G, et al. Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. JIMD Rep 2015;19:43-58. PMID 25681080
- 06
- Baber MD. A case of congenital cirrhosis of the liver with renal tubular defects akin to those in the Fanconi syndrome. Arch Dis Child 1956;31(159):335-9. PMID 13363479
- 07
- Barhold F, Meyer U, Neugebauer AK, et al. Hepatorenal tyrosinaemia: impact of a simplified diet on metabolic control and clinical outcome. Nutrients 2020;13(1):134. PMID 33396520
- 08
- Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 2014;37(5):745-52. PMID 24515874
- 09
- Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 2013;36(1):15-20. PMID 22456946
- 10
- Bendadi F, de Koning TJ, Visser G, et al. Impaired cognitive functioning in patients with tyrosinemia type 1 receiving nitisinone. J Pediatr 2014;164(2):398-401. PMID 24238861
- 11
- Bendon RW, Hug G. Glycogen accumulation in the pars recta of the proximal tubule in Fanconi syndrome. Pediatr Pathol 1986;6(4):411-29. PMID 3588439
- 12
- Berger R. Tyrosinemia. In: Blau N, Duran M, Blaskovics ME, editors. Physician's guide to the laboratory diagnosis of metabolic diseases. London: Chapman & Hall Medical, 1996:107-15.
- 13
- Berger R, van Faassen H, Smith GP. Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia. Clin Chim Acta 1983;134(1-2):129-41. PMID 6652907
- 14
- Bergeron A, D'Astous M, Timm DE, Tanguay RM. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. J Biol Chem 2001;276(18):15225-31. PMID 11278491
- 15
- Bergeron A, Jorquera R, Orejuela D, Tanguay RM. Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I. J Biol Chem 2006;281(9):5329-34. PMID 16317004
- 16
- Bergeron P, Laberge C, Grenier A. Hereditary tyrosinemia in the province of Quebec: prevalence at birth and geographic distribution. Clin Genet 1974;5(2):157-62. PMID 4829425
- 17
- Bhushan S, Noble C, Balouch F, et al. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization. Pediatr Transplant 2022;26(7):e14334. PMID 35698261
- 18
- Bliksrud YT, Brodtkorb E, Backe PH, Woldseth B, Rootwelt H. Hereditary tyrosinemia type 1 in Norway: Incidence and three novel small deletions in the fumarylacetoacetase gene. Scand J Clin Lab Invest 2012;72(5):369-73. PMID 22554029
- 19
- Bodegard G, Gentz J, Lindblad B, Lindstedt S, Zetterström R. Hereditary tyrosinemia. 3. On the differential diagnosis and the lack of effect of early dietary treatment. Acta Paediatr Scand 1969;58(1):37-48. PMID 5789740
- 20
- Bryson TE, Anglin CM, Bridges PH, Cottle RN. Nuclease-mediated gene therapies for inherited metabolic diseases of the liver. Yale J Biol Med 2017;90(4):553-66. PMID 29259521
- 21
- Cao YY, Zhang YL, Du J, et al. Compound mutation (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type 1 in a Chinese patient. Chin Med J (Engl) 2012;125(12):2132-6. PMID 22884142
- 22
- Chen J, Sun J, Li X, Du M. Identification and functional characterization of a novel homozygous intronic variant in the fumarylacetoacetate hydrolase gene in a Chinese patient with tyrosinemia type 1. BMC Med Genomics 2022;15(1):251. PMID 36463171
- 23
- Cheng Q, Wei T, Jia Y, et al. Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv Mater 2018;30(52):e1805308. PMID 30368954
- 24
- Chi H, Gan C, Jiang Y, et al. The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1). Mol Genet Genomic Med 2023;11(1):e2090. PMID 36369907
- 25
- Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med 2017;19(12). PMID 28771246
- 26
- Christensen E, Jacobsen BB, Gregersen N, et al. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia. Clin Chim Acta 1981;116(3):331-41. PMID 7296896
- 27
- Daly A, Evans S, Pinto A, Ashmore C, MacDonald A. Casein glycomacropeptide: an alternative protein substitute in tyrosinemia type I. Nutrients 2021;13(9):3224. PMID 34579102
- 28
- Das AM. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1). Appl Clin Genet 2017;10:43-8. PMID 28769581
- 29
- Demers SI, Russo P, Lettre F, Tanguay RM. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. Hum Pathol 2003;34(12):1313-20. PMID 14691918
- 30
- Dreumont N, Poudrier JA, Bergeron A, Levy HL, Baklouti F, Tanguay RM. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation. BMC Genet 2001;2:9. PMID 11476670
- 31
- El-Karaksy H, Abdullatif HM, Ghobrial CM, et al. Clinical experience with hepatorenal tyrosinemia from a single Egyptian center. PLoS One 2022;17(5):e0268017. PMID 35536841
- 32
- Endo F, Sun MS. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J Inherit Metab Dis 2002;25(3):227-34. PMID 12137232
- 33
- Fernandes J, Saudubray J, Van den Berghe G, Walter JH, editors. Inborn metabolic diseases. 4th edition. Heidelberg, Germany: Springer Medtzin Verlag, 2006:561.
- 34
- Fernandez-Lainez C, Ibarra-Gonzalez I, Belmont-Martinez L, Monroy-Santoyo S, Guillen-Lopez S, Vela-Amieva M. Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico. Ann Hepatol 2014;13(2)265-72. PMID 24552869
- 35
- Fritzell S, Jagenburg R, Schnurer LB. Familial cirrhosis of the liver, renal tubular defects with rickets and impaired tyrosine metabolism. Acta Paediatr 1964;53:18-32. PMID 14114313
- 36
- Gentz J, Jagenburg M, Zetterström R. Tyrosinemia: an inborn error of tyrosine metabolism with cirrhosis of the liver and multiple renal tubular defects (de Toni-Debre-Fanconi Syndrome). J Pediatr 1965;66:670-96. PMID 14271358
- 37
- Gentz J, Johansson S, Lindblad B, Lindstedt S, Zetterström R. Exertion of delta-aminolevulinic acid in hereditary tyrosinemia. Clin Chim Acta 1969;23(2):257-63. PMID 5764904
- 38
- Gentz J, Lindblad B, Lindstedt S, Levy L, Shasteen W, Zetterstrom R. Dietary treatment in tyrosinemia (tyrosinosis). With a note on the possible recognition of the carrier state. Am J Dis Child 1967;113(1):31-7. PMID 6015903
- 39
- Gjessing LR, Halvorsen S. Hypermethioninemia in acute tyrosinosis. Lancet 1965;2:1132-3.
- 40
- Gonzalez-Lamuno D, Sánchez-Pintos P, Andrade F, Couce ML, Aldámiz-Echevarría L. Treatment adherence in tyrosinemia type 1 patients. Orphanet J Rare Dis 2021;16(1):256. PMID 34082789
- 41
- Grenier A, Lescault A, Laberge C, Gagné R, Mamer O. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia. Clin Chim Acta 1982;123(1-2):93-9. PMID 7116642
- 42
- Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 2001;21(4):563-71. PMID 11745044
- 43
- Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 1994;331(6):353-7. PMID 8028615
- 44
- Haghighi-Kakhki H, Rezazadeh J, Ahmadi-Shadmehri A. Identification of a combined missense/splice-site mutation in FAH causing tyrosinemia type 1. J Pediatr Endocrinol Metab 2014;27(7-8):795-8. PMID 24756054
- 45
- Halvorsen S, Gjessing LR. Studies on tyrosinosis: 1, effect of low-tyrosine and low-phenylalanine diet. Br Med J 1964;2:1171-3. PMID 14190487
- 46
- Holme E. Disorders of tyrosine degradation. In: Blau N, Duran M, Blaskovics ME, Gibson K, editors. Physician's guide to the laboratory diagnosis of metabolic diseases. 2nd edition. Berlin, Germany: Springer, 2003:141-53.
- 47
- Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998;21(5):507-17. PMID 9728331
- 48
- Kitagawa T. Hepatorenal tyrosinemia. Proc Jpn Acad Ser B Phys Biol Sci 2012;88(5):192-200. PMID 22687740
- 49
- Kramer S, Becker D, Viljoen D. Significance of the porphyrin precursors delta-aminolaevulinic acid (ALA) and porphobilinogen (PBG) in the acute attack of porphyria. S Afr Med J 1973;47(38):1735-8. PMID 4270402
- 50
- Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P. Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 1994;94(4):1657-61. PMID 7929843
- 51
- Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 1993;91(4):1816-21. PMID 8473520
- 52
- Labelle Y, Phaneuf D, Leclerc B, Tanguay RM. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet 1993;2(7):941-6. PMID 8364576
- 53
- Laberge C, Dallaire L. Genetic aspects of tyrosinemia in the Chicoutimi region. Can Med Assoc J 1967;97(18):1099-101. PMID 6057677
- 54
- Larochelle J, Privé L, Bélanger M, et al. Hereditary tyrosinemia. I. Clinical and biological study of 62 cases [Article in French]. Pediatrie 1973;28(1):5-18. PMID 4715467
- 55
- Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 1977;74(10):4641-5. PMID 270706
- 56
- Maiorana A, Malamisura M, Emma F, Boenzi S, Di Ciommo VM, Dionisi-Vici C. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1. Mol Genet Metab 2014;113(3):188-93. PMID 25172236
- 57
- McDiarmid SV. Renal function in pediatric liver transplant patients. Kidney Int Suppl 1996;53:S77-84. PMID 8770996
- 58
- Medes G. A new error of tyrosine metabolism: tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem J 1932;26(4):917-40. PMID 16744947
- 59
- Menon J, Shanmugam N, Valamparampil JJ, et al. Liver transplantation: a safe and definitive alternative to lifelong nitisinone for tyrosinemia type 1. Indian J Pediatr 2022;89(5):438-44. PMID 34398413
- 60
- Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322(7):432-7. PMID 2153931
- 61
- Mitchell GA, Yang H. Remaining challenges in the treatment of tyrosinemia from the clinician's viewpoint. Adv Exp Med Biol 2017;959:205-13. PMID 28755198
- 62
- Mohamed S, Kambal MA, Al Jurayyan NA, et al. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes 2013;6:362. PMID 24016420
- 63
- Nakamura K, Tanaka Y, Mitsubuchi H, Endo F. Animal models of tyrosinemia. J Nutr 2007;137(6 Suppl 1):1556S-1560S. PMID 17513424
- 64
- Nasrallah F, Hammami MB, Ben Rhouma H, et al. Clinical and biochemical profile of tyrosinemia type 1 in Tunisia. Clin Lab 2015;61(5-6):487-92. PMID 26118180
- 65
- Onenli Mungan N, Yıldızdaş D, Kör D, et al. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metab Brain Dis 2016;31(5):1181-3. PMID 27188289
- 66
- Paradis K. Tyrosinemia: the Quebec experience. Clin Invest Med 1996;19(5):311-6. PMID 8889268
- 67
- Paulk NK, Wursthorn K, Wang Z, Finegold MJ, Kay MA, Grompe M. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 2010;51(4):1200-8. PMID 20162619
- 68
- Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 1992;90(4):1185-92. PMID 1401056
- 69
- Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab 1998;64(2):119-25. PMID 9705236
- 70
- Rootwelt H, Berger R, Gray G, Kelly DA, Coşkun T, Kvittingen EA. Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1. Am J Hum Genet 1994;55(4):653-8. PMID 7942842
- 71
- Roth KS, Carter BE, Higgins ES. Succinylacetone effects on renal tubular phosphate metabolism: a model for experimental renal Fanconi syndrome. Proc Soc Exp Biol Med 1991;196(4):428-31. PMID 1672565
- 72
- Roth KS, Carter BE, Moses LC, Spencer PD. On rat renal aminolevulinate transport and metabolism in experimental Fanconi syndrome. Biochem Med Metab Biol 1990;44(3):238-46. PMID 2288767
- 73
- Roth KS, Medow MS, Moses LC, Spencer PD, Schwarz SM. Renal Fanconi syndrome: developmental basis for a new animal model with relevance to human disease. Biochim Biophys Acta 1989;987(1):38-46. PMID 2597685
- 74
- Roth KS, Spencer PD, Higgins ES, Spencer RF. Effects of succinylacetone on methyl alpha-D-glucoside uptake by the rat renal tubule. Biochim Biophys Acta 1985;820(1):140-6. PMID 4052413
- 75
- Sakai K, Kitagawa T. An atypical case of tyrosinosis (l-para- hydroxyphenyllactic aciduria) Part 1. Clinical and laboratory findings. Jikeikai Med J 1957a;4:1-10.
- 76
- Sakai K, Kitagawa T. An atypical case of tyrosinosis (l-para-hydroxyphenyllactic aciduria) Part 2. A research on the metabolic block. Jikeikai Med J 1957b;4:11-5.
- 77
- Sakai K, Kitagawa T, Yoshikawa K. An atypical case of tyrosinosis (l-para-hydroxyphenyllactic aciduria) III. The outcome of the patients. Pathological and biochemical observations on the organ tissues. Jikeikai Med J 1959;6:15-24.
- 78
- Sassa S, Fujita H, Kappas A. Succinylacetone and delta-aminolevulinic acid dehydratase in hereditary tyrosinemia: immunochemical study of the enzyme. Pediatrics 1990;86(1):84-6. PMID 2359685
- 79
- Sassa S, Kappas A. Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver. Trans Assoc Am Physicians 1982;95:42-52. PMID 7182986
- 80
- Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 1983;71(3):625-34. PMID 6826727
- 81
- Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type 1. J Inherit Metab Dis 2012;35(5):831-6. PMID 22307209
- 82
- Scott CR. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet 2006;142C(2):121-6. PMID 16602095
- 83
- Scriver CR, Clow CL, Siverberg M. Hypermethioninemia in acute tyrosinosis. Lancet 1966;1:153-4.
- 84
- Seda Neto J, Leite KM, Porta A, et al. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1. Pediatr Blood Cancer 2014;61(9):1584-9. PMID 24852359
- 85
- Shin JH, Jung S, Ramakrishna S, Kim HH, Lee J. In vivo gene correction with targeted sequence substitution through microhomology-mediated end joining. Biochem Biophys Res Commun 2018;502(1):116-22. PMID 29787760
- 86
- Spencer PD, Medow MS, Moses LC, Roth KS. Effects of succinylacetone on the uptake of sugars and amino acids by brush border vesicles. Kidney Int 1988;34(5):671-7. PMID 3199678
- 87
- Spencer PD, Roth KS. Effects of succinylacetone on amino acid uptake in the rat kidney. Biochem Med Metab Biol 1987;37(1):101-9. PMID 3566973
- 88
- Spiekerkoetter U, Couce ML, Das AM, et al. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study. Lancet Diabetes Endocrinol 2021;9(7):427-35. PMID 34023005
- 89
- Sun MS, Hattori S, Kubo S, Awata H, Matsuda I, Endo F. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice. J Am Soc Nephrol 2000;11(2):291-300. PMID 10665936
- 90
- Tang Y, Kong Y. Hereditary tyrosinemia type I: newborn screening, diagnosis and treatment. Zhejiang Da Xue Xue Bao Yi Xue Ban 2021;50(4):514-23. PMID 34704422
- 91
- Taniguchi K, Gjessing LR. Studies on tyrosinosis: 2, activity of the transaminase, parahydroxy-phenylpyruvate oxidase, and homogentisic-acid oxidase. Br Med J 1965;1:968-9. PMID 14260629
- 92
- van Ginkel WG, Gouw AS, van der Jagt EJ, de Jong KP, Verkade HJ, van Spronsen FJ. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP. Pediatrics 2015;135(3):e749-52. PMID 25667247
- 93
- van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-term outcomes and practical considerations in the pharmacological management of tyrosinemia type 1. Paediatr Drugs 2019b;21(6):413-26. PMID 31667718
- 94
- van Ginkel WG, van Reemst HE, Kienstra NS, et al. The effect of various doses of phenylalanine supplementation on blood phenylalanine and tyrosine concentrations in tyrosinemia type 1 patients. Nutrients 2019a;11(11):2816. PMID 31752110
- 95
- van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20(5):1187-91. PMID 7927251
- 96
- van Vliet K, van Ginkel WG, Jahja R, et al. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated tyrosinemia type 1 patients. Orphanet J Rare Dis 2019;14(1):285. PMID 31801588
- 97
- Wang Z, Lisowski L, Finegold MJ, Nakai H, Kay MA, Grompe M. AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. Mol Ther 2012;20(10):1902-11. PMID 22990673
- 98
- Wyss PA, Boynton SB, Chu J, Spencer RF, Roth KS. Physiological basis for an animal model of the renal Fanconi syndrome: use of succinylacetone in the rat. Clin Sci (Lond). 1992;83(1):81-7. PMID 1325326
- 99
- Wyss PA, Carter BE, Boynton SB, Connor E, Fowler B, Roth KS. Renal heme metabolism in hereditary tyrosinemia: use of succinylacetone in rat renal tubules. Biochim Biophys Acta 1991;1070(2):300-4. PMID 1764448
- 100
- Yang H, Al-Hertani W, Cyr D, et al. Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency. J Med Genet 2017a;54(4):241-7. PMID 27876694
- 101
- Yang H, Rossignol F, Cyr D, et al. Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient FAH alleles. Mol Genet Metab Rep 2017b;14:55-8. PMID 29326876
- 102
- Zetterström R. Tyrosinosis. Ann N Y Acad Sci 1963;111:220-6. PMID 14085846
- 103
- Zoggeler T, Ramoser G, Holler A, et al. Nitisinone treatment during two pregnancies and breastfeeding in a woman with tyrosinemia type 1 - a case report. J Pediatr Endocrinol Metab 2021;35(2):259-65. PMID 34506697
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Former Authors
- Etresia van Dyk PhD
Patient Profile
- Age range of presentation
-
- 0 month to 5 years
- Sex preponderance
-
- male=female
- Heredity
-
- autosomal recessive
- Population groups selectively affected
-
- French-Canadian
- Occupation groups selectively affected
-
- none
ICD & OMIM codes
- ICD-10
-
- Tyrosinemia type 1: E70.2
- ICD-11
-
- Tyrosinaemia type 1: 5C50.11
- OMIM
-
- Tyrosinemia type 1: #276700
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neurogenetic Disorders
Pyruvate carboxylase deficiency
Nov. 09, 2024
-
Neurogenetic Disorders
Pelizaeus-Merzbacher disease
Oct. 31, 2024
-
Neurogenetic Disorders
Vanishing white matter disease
Oct. 30, 2024
-
Neurogenetic Disorders
Wilson disease
Oct. 23, 2024
-
Neurogenetic Disorders
Aromatic L-amino acid decarboxylase deficiency
Sep. 13, 2024
-
Stroke & Vascular Disorders
White matter abnormalities in the brain
Sep. 12, 2024
-
Neurogenetic Disorders
Hypermethioninemia
Sep. 12, 2024